CX Institutional’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.7M | Sell |
78,286
-11,667
| -13% | -$2.51M | 0.57% | 42 |
|
|
2026
Q1 | $19.6M | Buy |
89,953
+4,070
| +5% | +$903K | 0.6% | 36 |
|
|
2025
Q4 | $19.6M | Buy |
85,883
+481
| +0.6% | +$110K | 0.59% | 37 |
|
|
2025
Q3 | $19.8M | Buy |
85,402
+20,097
| +31% | +$4.09M | 0.6% | 36 |
|
|
2025
Q2 | $12.1M | Sell |
65,305
-4,153
| -6% | -$772K | 0.42% | 46 |
|
|
2025
Q1 | $14.6M | Sell |
69,458
-811
| -1% | -$158K | 0.55% | 43 |
|
|
2024
Q4 | $12.5M | Sell |
70,269
-105
| -0.1% | -$19.3K | 0.5% | 45 |
|
|
2024
Q3 | $13.9M | Buy |
70,374
+11,227
| +19% | +$2.1M | 0.62% | 46 |
|
|
2024
Q2 | $10.1M | Buy |
59,147
+487
| +0.8% | +$80.7K | 0.48% | 61 |
|
|
2024
Q1 | $10.7M | Buy |
58,660
+5,125
| +10% | +$883K | 0.51% | 53 |
|
|
2023
Q4 | $8.3M | Buy |
53,535
+10
| +0% | +$1.46K | 0.44% | 65 |
|
|
2023
Q3 | $7.98M | Buy |
53,525
+12,052
| +29% | +$1.77M | 0.44% | 64 |
|
|
2023
Q2 | $5.59M | Sell |
41,473
-2,553
| -6% | -$374K | 0.29% | 96 |
|
|
2023
Q1 | $7.05M | Buy |
44,026
+4,975
| +13% | +$761K | 0.38% | 73 |
|
|
2022
Q4 | $6.31M | Sell |
39,051
-20,814
| -35% | -$3.19M | 0.38% | 62 |
|
|
2022
Q3 | $8.04M | Buy |
59,865
+47,481
| +383% | +$6.81M | 0.56% | 47 |
|
|
2022
Q2 | $1.9M | Buy |
12,384
+75
| +0.6% | +$11.5K | 0.14% | 177 |
|
|
2022
Q1 | $2M | Sell |
12,309
-1,131
| -8% | -$164K | 0.16% | 151 |
|
|
2021
Q4 | $1.82M | Buy |
13,440
+422
| +3% | +$49.8K | 0.14% | 157 |
|
|
2021
Q3 | $1.4M | Sell |
13,018
-229
| -2% | -$26.2K | 0.11% | 188 |
|
|
2021
Q2 | $1.49M | Buy |
13,247
+479
| +4% | +$53.9K | 0.12% | 181 |
|
|
2021
Q1 | $1.38M | Buy |
12,768
+107
| +0.8% | +$11.4K | 0.12% | 179 |
|
|
2020
Q4 | $1.36M | Buy |
12,661
+786
| +7% | +$75.5K | 0.13% | 175 |
|
|
2020
Q3 | $1.04M | Buy |
11,875
+228
| +2% | +$21.5K | 0.11% | 170 |
|
|
2020
Q2 | $1.14M | Buy |
11,647
+2,784
| +31% | +$245K | 0.15% | 144 |
|
|
2020
Q1 | $675K | Sell |
8,863
-93
| -1% | -$7.92K | 0.11% | 151 |
|
|
2019
Q4 | $793K | Sell |
8,956
-405
| -4% | -$33.6K | 0.14% | 125 |
|
|
2019
Q3 | $709K | Sell |
9,361
-1,781
| -16% | -$122K | 0.11% | 147 |
|
|
2019
Q2 | $810K | Buy |
11,142
+1,801
| +19% | +$142K | 0.13% | 138 |
|
|
2019
Q1 | $753K | Sell |
9,341
-7,181
| -43% | -$587K | 0.13% | 142 |
|
|
2018
Q4 | $1.52M | Sell |
16,522
-13,080
| -44% | -$1.15M | 0.32% | 74 |
|
|
2018
Q3 | $2.8M | Buy |
29,602
+1,997
| +7% | +$189K | 0.93% | 37 |
|
|
2018
Q2 | $2.56M | Buy |
+27,605
| New | +$2.7M | 0.95% | 36 |
|
Other funds holding ABBV
CX Institutional's ABBV Position: Q2 2026 in Review
CX Institutional reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $2.51M and leaving 78,286 shares worth $19.7M. The position accounts for 0.57% of the portfolio, ranked #42.
CX Institutional first reported a position in ABBV in Q2 2018 and has held it in 33 quarters since. The position peaked at $19.8M in Q3 2025. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- CX Institutional held 78,286 shares of AbbVie worth $19.7M as of Q2 2026.
- CX Institutional sold 11,667 AbbVie shares in Q2 2026, an estimated $2.51M.
- AbbVie made up 0.57% of CX Institutional's portfolio in Q2 2026, its #42 holding.
- CX Institutional first reported a position in AbbVie in Q2 2018 and has held it in 33 quarters since.
- CX Institutional's AbbVie position peaked at $19.8M in Q3 2025.
- 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.